Clinical Trial Update: Study of the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of Alirocumab SAR236553 (REGN727) [Phase 1]

View source ↗

Summary

A Phase 1 study assessed tolerability, safety, pharmacokinetics and pharmacodynamics of Alirocumab (REGN727/SAR236553) in hypercholesterolemia; the trial has co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia

Drugs mentioned

• Praluent (alirocumab)

Snippet

Sponsor: Sanofi | Conditions: Hypercholesterolemia | Phase 1 | Status: COMPLETED